Skip to main content

Table 2 Baseline Demographics and Characteristics

From: Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

  Eptinezumab 100 mg Eptinezumab 300 mg Eptinezumab 1000 mg Placebo
N = 701 N = 695 N = 81 N = 791
Mean age, years (SD) 39.9 (11.11) 40.1 (10.84) 38.6 (10.81) 39.3 (10.96)
Sex: Female, n (%) 590 (84.2) 611 (87.9) 67 (82.7) 686 (86.7)
Race, n (%)
 White 636 (90.7) 623 (89.6) 66 (81.5) 677 (85.6)
 Black / African American 50 (7.1) 54 (7.8) 10 (12.3) 84 (10.6)
 Asian 2 (0.3) 3 (0.4) 4 (4.9) 7 (0.9)
 American Indian / Alaska Native 1 (0.1) 3 (0.4) 0 3 (0.4)
 Native Hawaiian / other Pacific Islander 1 (0.1) 2 (0.3) 0 2 (0.3)
 Multiple races 9 (1.3) 8 (1.2) 1 (1.2) 13 (1.6)
 Other 2 (0.3) 1 (0.1) 0 5 (0.6)
 Not reported 0 1 (0.1) 0 0
Mean BMI, kg/m2 27.6 (6.15) 27.3 (5.91) 27.5 (5.17) 27.9 (6.14)
Preventive migraine medication use, n (%)* 52/478 (10.9) 62/471 (13.2) 49/487 (10.1)
Cardiovascular risk factors, n (%)
 Hypertension-related 36 (5.1) 26 (3.7) 1 (1.2) 28 (3.5)
 Hyperlipidemia-related 48 (6.8) 45 (6.5) 5 (6.2) 45 (5.7)
 Diabetes-related 3 (0.4) 0 1 (1.2) 5 (0.6)
 History of ischemic CV events/procedures 4 (0.6) 3 (0.4) 0 3 (0.4)
 Obesity (Class 1 or 2), BMI ≥30 kg/m2 226 (32.2) 197 (28.3) 26 (32.1) 265 (33.5)
 Male ≥45 years 43 (6.1) 24 (3.5) 4 (4.9) 38 (4.8)
 Female ≥55 years 63 (9.0) 57 (8.2) 2 (2.5) 49 (6.2)
 Black or African American race 50 (7.1) 54 (7.8) 10 (12.3) 84 (10.6)
  ≥ 1 CV risk factor 350 (49.9) 316 (45.5) 41 (50.6) 382 (48.3)
  ≥ 2 CV risk factors 97 (13.8) 83 (11.9) 7 (8.6) 112 (14.2)
Medical/Surgical CV history, n (%)
 Angina pectoris 0 1 (0.1) 0 0
 Aortic valve incompetence 1 (0.1) 0 0 0
 Arrhythmia 0 0 1 (1.2) 1 (0.1)
 Supraventricular arrhythmia 0 1 (0.1) 0 0
 Atrioventricular block, first degree 0 0 0 1 (0.1)
 Bradycardia 2 (0.3) 4 (0.6) 0 4 (0.5)
 Bundle branch block, left 1 (0.1) 0 0 0
 Bundle branch block, right 0 2 (0.3) 0 2 (0.3)
 Cardiomegaly 1 (0.1) 0 0 0
 Cardiomyopathy 0 1 (0.1) 0 0
 Mitral valve incompetence 1 (0.1) 0 0 1 (0.1)
 Mitral valve prolapse 1 (0.1) 4 (0.6) 0 6 (0.8)
 Palpitations 3 (0.4) 2 (0.3) 0 5 (0.6)
 POTS 1 (0.1) 0 0 0
 Sinus arrhythmia 1 (0.1) 1 (0.1) 0 0
 Sinus bradycardia 0 0 0 2 (0.3)
 Sinus tachycardia 1 (0.1) 1 (0.1) 0 1 (0.1)
 Supraventricular tachycardia 1 (0.1) 2 (0.3) 0 1 (0.1)
 Tachycardia 0 2 (0.3) 1 (1.2) 5 (0.6)
 Tricuspid valve incompetence 1 (0.1) 0 0 0
 Ventricular extrasystoles 1 (0.1) 0 0 1 (0.1)
 Ventricular tachycardia 0 0 0 1 (0.1)
  1. *Use of a stable preventive migraine medication regimen was permitted in CM studies, and as such, the number of patients reflects only those studies. BMI body mass index, CM Chronic migraine, CV Cardiovascular, POTS Postural orthostatic tachycardia syndrome, SD Standard deviation